Revenue Update on Harvard Bioscience(NASDAQ:HBIO)

Harvard Bioscience(NASDAQ:HBIO) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $26.14M. Analysts estimated a revenue of $26.64M. Earnings per share were $0.03. Analysts had estimated an EPS of $0.03.

Harvard Bioscience (HBIO) remained unchanged at the close of Thursday session. Even as the volume increased to 19,408 ,the shares failed to make any impression and ended at 0 points or 0.00% at $2.8. The trading session commenced at $2.82 and the stock hit a high of $2.9 and touched $2.8 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $4.99 and the 52-week low is $2.41. The company has a market cap of $95 M and has approximately 3,40,69,549 outstanding shares.

Several Insider Transactions has been reported to the SEC. On Jan 11, 2016, Earl R Lewis (director) purchased 27,221 shares at $3.28 per share price.Also, On Dec 11, 2015, Jeffrey Duchemin (CEO) purchased 10,000 shares at $3.37 per share price.On Dec 3, 2015, George Uveges (director) purchased 3,000 shares at $3.32 per share price, according to the Form-4 filing with the securities and exchange commission.

Harvard Bioscience Inc. is a developer manufacturer and marketer of a range of specialized products apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies universities and government laboratories across the world. The Company’s core product range is organized into five product families: Fluidics Lab Equipment and Supplies Molecular Analysis Cell Physiology and Animal Physiology. Its products include instruments consumables and systems that are made up of several individual products. The Company’s brands include Harvard Apparatus KD Scientific Denville Scientific AHN Hoefer Biochrom BTX Warner Instruments MCS HEKA Hugo Sachs Elektronik Panlab Coulbourn Instruments TBSI and CMA Microdialysis. The Company has sales and manufacturing operations in the United States the United Kingdom Germany Sweden Spain France Canada and China.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Harvard Bioscience - Is it time to Sell?

Top Brokerage Firms are advising their investors on Harvard Bioscience. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.